Meds & supplements › Asfotase alfa
Medicine · Tissue-nonspecific Alkaline Phosphatase
Asfotase alfa
STRENSIQ ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- STRENSIQ ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).
Side effects, and when to stop
The following adverse reactions are described below and elsewhere in the labeling:
- Hypersensitivity Reactions
- Lipodystrophy
- Ectopic Calcifications
- Possible Immune-Mediated Clinical Effects
Who should not take it
None.
Storing it
STRENSIQ vials must be stored in the original carton until the time of use under refrigerated conditions at 2°C to 8°C (36°F to 46°F) and protected from light.
Once removed from refrigeration, STRENSIQ should be administered within 3 hours.
Do not use beyond the expiration date stamped on the carton.
DO NOT FREEZE OR SHAKE.
Vials are for one time use only. Discard any unused product.
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Asfotase alfa; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/asfotase-alfa
- APA 7th
sofidex. (2026, August 2). Asfotase alfa. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/asfotase-alfa
- AMA 11th
Asfotase alfa. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/asfotase-alfa
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.